6Saunthararajah Y, Nakamura R, Nam JM, et al. HLA-DR15 (DtL2) is overrepresented in myelodysplastic syndrome and aplastic anemia and predicts a response to immunosuppression in myelodysplastic syndrome. Blood, 2002 ; 100 (5) : 1570 - 1574.
7Ihan O, Beksac M, Arslan O, et al. HLA DR2 : a predictive marker in response to cyclosporine therapy in aplastic anemia. Int J Hematol, 1997 ;66(3) :291 -295.
8Maciejewski JP, Follmann D, Nakamura R, et al. Increased frequency of HLA-DR2 in patients with paroxysmal nocturnal hemoglobinuria and the PNH/aplastic anemia syndrome. Blood, 2001 ;98 (13) :3513 -3519.
9Olerup O, Zetterquist H. HLA-DR typing by PCR amplification with sequence-specific primers (PCR-SSP) in 2 hours: an ahemative to serological DR typing in clinical practice including donor-recipient matching in cadaveric transplantation. Tissue Antigens, 1992; 39 (5) :225 -235.
10Saunthararajah Y, Nakamura R, Wesley R, et al. A simple method to predict response to immunosuppressive therapy in patients with myelodysplastic syndrome. Blood, 2003 ; 102 ( 8 ) :3025 - 3027.
